| abstract |
17α-hydroxylase / C17,20 lyase inhibitor [eg (3β) -17- (pyridin-3-yl) androst-5,16-dien-3-ol or a pharmaceutically acceptable salt or ester thereof And an AKT inhibitor [eg, N-{(1S) -2-amino-1-[(3-fluorophenyl) methyl] ethyl} -5-chloro-4- (4-chloro-1-methyl-1H -Pyrazol-5-yl) -2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and any additional antineoplastic agent; a pharmaceutical composition comprising the combination, and Use of the combinations and compositions in conditions where inhibition of 17α-hydroxylase / C17,20 lyase and / or AKT inhibition is beneficial (eg, treatment of cancer) Law. [Selection figure] None |